NEW: Updated NCCN Multiple Myeloma Guidelines Strengthen MRD Testing Recommendations and Specifically Reference clonoSEQ
FDA-cleared and covered by Medicare, clonoSEQ meets the requirements of the updated guidelines and provides highly sensitive MRD testing across the treatment continuum in multiple myeloma. For more info about this exciting update, read our press release here.
Contact Us
Have a question about clonoSEQ? Fill out the form below
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.